JP2021181439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021181439A5 JP2021181439A5 JP2021109796A JP2021109796A JP2021181439A5 JP 2021181439 A5 JP2021181439 A5 JP 2021181439A5 JP 2021109796 A JP2021109796 A JP 2021109796A JP 2021109796 A JP2021109796 A JP 2021109796A JP 2021181439 A5 JP2021181439 A5 JP 2021181439A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- dose
- pharmaceutical composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004480 active ingredient Substances 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 16
- 102000018358 immunoglobulin Human genes 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 238000010254 subcutaneous injection Methods 0.000 claims description 11
- 239000007929 subcutaneous injection Substances 0.000 claims description 11
- 229940122551 CD40 antagonist Drugs 0.000 claims description 10
- 208000002557 hidradenitis Diseases 0.000 claims description 9
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 7
- 238000012423 maintenance Methods 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 206010016717 Fistula Diseases 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000003890 fistula Effects 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 238000011546 CRP measurement Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000009392 systemic autoimmunity Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024161056A JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19151461 | 2019-01-11 | ||
| EP19151461.1 | 2019-01-11 | ||
| JP2020539848A JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539848A Division JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161056A Division JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021181439A JP2021181439A (ja) | 2021-11-25 |
| JP2021181439A5 true JP2021181439A5 (enExample) | 2023-01-18 |
| JP7558900B2 JP7558900B2 (ja) | 2024-10-01 |
Family
ID=65019425
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539848A Pending JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
| JP2021109796A Active JP7558900B2 (ja) | 2019-01-11 | 2021-07-01 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
| JP2024161056A Withdrawn JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539848A Pending JP2021506953A (ja) | 2019-01-11 | 2020-01-09 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161056A Withdrawn JP2024178278A (ja) | 2019-01-11 | 2024-09-18 | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12435150B2 (enExample) |
| EP (1) | EP3908310A1 (enExample) |
| JP (3) | JP2021506953A (enExample) |
| KR (1) | KR20210114964A (enExample) |
| CN (1) | CN113271964A (enExample) |
| AU (1) | AU2020205839A1 (enExample) |
| BR (1) | BR112021013174A2 (enExample) |
| CA (1) | CA3125886A1 (enExample) |
| CL (1) | CL2021001829A1 (enExample) |
| IL (1) | IL284338A (enExample) |
| MX (1) | MX2021008305A (enExample) |
| TW (1) | TW202033558A (enExample) |
| WO (1) | WO2020144605A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061061A1 (en) * | 2020-09-21 | 2022-03-24 | Boehringer Ingelheim International Gmbh | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| WO2024261192A1 (en) * | 2023-06-20 | 2024-12-26 | Kymab Limited | Use of ox40 and ox40l modulators to treat hidradenitis suppurativa |
| WO2025147499A1 (en) * | 2024-01-03 | 2025-07-10 | Abbvie Inc. | Lutikizumab for use in a treatment of hidradenitis suppurativa |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025235683A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| RU2377254C2 (ru) | 2003-12-25 | 2009-12-27 | Кирин Фарма Кабусики Кайся | Мутанты анти-cd40 антитела |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| RS60612B1 (sr) | 2010-03-31 | 2020-08-31 | Boehringer Ingelheim Int | Anti-cd40 antitela |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| ES2711100T3 (es) | 2011-03-07 | 2019-04-30 | Celgene Corp | Métodos para tratar enfermedades usando compuestos isoindolina |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| UY36692A (es) | 2015-05-29 | 2016-12-30 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| RU2020117156A (ru) * | 2017-12-01 | 2022-01-04 | Эббви Инк. | Конъюгаты анти-cd40 антитела и лекарственного средства |
-
2020
- 2020-01-09 BR BR112021013174A patent/BR112021013174A2/pt not_active IP Right Cessation
- 2020-01-09 US US17/422,075 patent/US12435150B2/en active Active
- 2020-01-09 EP EP20701367.3A patent/EP3908310A1/en active Pending
- 2020-01-09 CA CA3125886A patent/CA3125886A1/en active Pending
- 2020-01-09 CN CN202080008145.XA patent/CN113271964A/zh active Pending
- 2020-01-09 TW TW109100800A patent/TW202033558A/zh unknown
- 2020-01-09 WO PCT/IB2020/050132 patent/WO2020144605A1/en not_active Ceased
- 2020-01-09 JP JP2020539848A patent/JP2021506953A/ja active Pending
- 2020-01-09 AU AU2020205839A patent/AU2020205839A1/en not_active Abandoned
- 2020-01-09 MX MX2021008305A patent/MX2021008305A/es unknown
- 2020-01-09 KR KR1020217024671A patent/KR20210114964A/ko not_active Withdrawn
-
2021
- 2021-06-23 IL IL284338A patent/IL284338A/en unknown
- 2021-07-01 JP JP2021109796A patent/JP7558900B2/ja active Active
- 2021-07-08 CL CL2021001829A patent/CL2021001829A1/es unknown
-
2024
- 2024-09-18 JP JP2024161056A patent/JP2024178278A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021181439A5 (enExample) | ||
| US6537549B2 (en) | Cytokine antagonists for the treatment of localized disorders | |
| JP2021119165A (ja) | Ｉｌ−１７抗体の医薬製品および安定した液体組成物 | |
| EP3792281A1 (en) | Methods of treating psoriasis using il-17 antagonists | |
| US20010016195A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| JP2024109762A (ja) | Ｉｌ－１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP7558900B2 (ja) | 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 | |
| US20230303677A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| US20030185826A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| US20230235041A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists | |
| CA3162052A1 (en) | Methods of treating lichen planus using interleukin-17 (il-17) antagonists | |
| Ma et al. | 11 Current Recommendations | |
| RU2021123408A (ru) | Антитела к cd40 для применения в лечении гнойного гидраденита | |
| Jedrzynski et al. | Biologics for Thyroid Eye Disease | |
| HK40037862A (en) | Methods of treating psoriasis using il-17 antagonists | |
| HK1183673A (en) | Methods of treating psoriasis using il-17 antagonists | |
| HK1183673B (en) | Methods of treating psoriasis using il-17 antagonists |